Pleiotropic mechanisms facilitated by resveratrol and its metabolites.
Resveratrol has demonstrated cancer chemopreventive activity in animal models and some clinical trials are underway. In addition, resveratrol was shown to promote cell survival, increase lifespan and mimic caloric restriction, thereby improving health and survival of mice on high-calorie diet. All of these effects are potentially mediated by the pleiotropic interactions of resveratrol with different enzyme targets including COX-1 (cyclo-oxygenase-1) and COX-2, NAD+-dependent histone deacetylase SIRT1 (sirtuin 1) and QR2 (quinone reductase 2). Nonetheless, the health benefits elicited by resveratrol as a direct result of these interactions with molecular targets have been questioned, since it is rapidly and extensively metabolized to sulfate and glucuronide conjugates, resulting in low plasma concentrations. To help resolve these issues, we tested the ability of resveratrol and its metabolites to modulate the function of some known targets in vitro. In the present study, we have shown that COX-1, COX-2 and QR2 are potently inhibited by resveratrol, and that COX-1 and COX-2 are also inhibited by the resveratrol 4'-O-sulfate metabolite. We determined the X-ray structure of resveratrol bound to COX-1 and demonstrate that it occupies the COX active site similar to other NSAIDs (non-steroidal anti-inflammatory drugs). Finally, we have observed that resveratrol 3- and 4'-O-sulfate metabolites activate SIRT1 equipotently to resveratrol, but that activation is probably a substrate-dependent phenomenon with little in vivo relevance. Overall, the results of this study suggest that in vivo an interplay between resveratrol and its metabolites with different molecular targets may be responsible for the overall beneficial health effects previously attributed only to resveratrol itself.
Calamini
Barbara
B
Department of Medicinal Chemistry and Pharmacognosy and Center for Pharmaceutical Biotechnology, College of Pharmacy, University of Illinois at Chicago, Chicago, IL 60607, USA. b-calamini@northwestern.edu
Ratia
Kiira
K
Malkowski
Michael G
MG
Cuendet
Muriel
M
Pezzuto
John M
JM
Santarsiero
Bernard D
BD
Mesecar
Andrew D
AD
D000818:Animals; D016588:Anticarcinogenic Agents / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D020134:Catalytic Domain; D018360:Crystallography, X-Ray; D051545:Cyclooxygenase 1 / Q000737:chemistry / Q000378:metabolism; D051546:Cyclooxygenase 2 / Q000737:chemistry / Q000378:metabolism; D052246:Cyclooxygenase 2 Inhibitors / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D016861:Cyclooxygenase Inhibitors / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D051379:Mice; D008958:Models, Molecular; D011808:Quinone Reductases / Q000037:antagonists & inhibitors; D000077185:Resveratrol; D056564:Sirtuin 1 / Q000378:metabolism; D013267:Stilbenes / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology*
D016588:Anticarcinogenic Agents; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D013267:Stilbenes; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; C419642:NRH - quinone oxidoreductase2; D011808:Quinone Reductases; C447939:SIRT1 protein, human; D056564:Sirtuin 1; D000077185:Resveratrol
Mol Carcinog. 2008 Oct;47(10):797-805
18381589
Biochemistry. 2004 Sep 14;43(36):11417-26
15350128
Free Radic Biol Med. 2008 Jul 15;45(2):136-45
18423413
J Biol Chem. 2010 Mar 12;285(11):8340-51
20061378
Nat Protoc. 2006;1(4):1915-21
17487176
J Biol Chem. 2005 Mar 18;280(11):9780-5
15640142
Biochemistry. 2004 Apr 20;43(15):4538-47
15078100
J Pharm Pharmacol. 2003 Mar;55(3):307-12
12724035
J Mol Biol. 1982 Oct 25;161(2):269-88
7154081
Chem Biol Drug Des. 2009 Dec;74(6):619-24
19843076
Arch Biochem Biophys. 2000 Aug 1;380(1):39-45
10900130
Nature. 2007 Nov 29;450(7170):712-6
18046409
Prostaglandins Other Lipid Mediat. 1998 Jun;56(2-3):131-43
9785383
Drugs Exp Clin Res. 1999;25(2-3):115-20
10370873
Nature. 2003 Nov 13;426(6963):119
14614475
Nature. 2003 Sep 11;425(6954):191-6
12939617
Clin Chim Acta. 1995 Jun 15;237(1-2):155-87
7664473
Biochem Biophys Res Commun. 2004 Oct 22;323(3):743-9
15381063
Science. 2000 Sep 15;289(5486):1933-7
10988074
Acta Crystallogr D Biol Crystallogr. 1998 Sep 1;54(Pt 5):905-21
9757107
Nucleic Acids Res. 2000 Jan 1;28(1):235-42
10592235
Methods Enzymol. 1997;276:307-26
27754618
J Biol Chem. 1998 Aug 21;273(34):21875-82
9705326
Biochem J. 1999 May 1;339 ( Pt 3):607-14
10215599
J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Apr 1;848(2):182-7
17097357
Rapid Commun Mass Spectrom. 2003;17(4):307-13
12569440
Biochemistry. 1999 Dec 14;38(50):16636-47
10600126
Acta Crystallogr A. 1991 Mar 1;47 ( Pt 2):110-9
2025413
J Biol Chem. 2005 Apr 29;280(17):17038-45
15684413
Biochem Pharmacol. 2006 Jul 28;72(3):366-76
16765324
J Biol Chem. 2004 May 21;279(21):22727-37
15020596
Nature. 2006 Nov 16;444(7117):337-42
17086191
Clin Chim Acta. 1995 Mar 31;235(2):207-19
7554275
Cancer Res. 2000 Jul 1;60(13):3477-83
10910059
J Biol Chem. 2002 Nov 29;277(48):46131-9
12351651
Proc Natl Acad Sci U S A. 1975 Aug;72(8):3073-6
810797
Drug Metab Dispos. 2004 Dec;32(12):1377-82
15333514
Nat Biotechnol. 2010 Mar;28(3):185-6
20212464
Nature. 2004 Aug 5;430(7000):686-9
15254550
Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1246-52
17548692
Cancer Prev Res (Phila). 2008 Jul;1(2):135-45
19138946
Arch Biochem Biophys. 2000 Mar 1;375(1):195-200
10683267
Bioorg Med Chem. 2004 Nov 1;12(21):5571-8
15465334
Br J Cancer. 2006 Nov 6;95(9):1229-33
17031400
Science. 1997 Jan 10;275(5297):218-20
8985016
Biochem J. 2007 May 15;404(1):1-13
17447894
Cancer Res. 2000 Aug 1;60(15):4179-86
10945627
Pharm Res. 2002 Dec;19(12):1907-14
12523673
J Biol Chem. 2005 Apr 29;280(17):17187-95
15749705
Science. 1983 Aug 19;221(4612):709-13
6879170